MedTrace Logo

Basal Like Bladder Cancer : Signature and Therapeutic

NCT02648100 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 911

Last updated 2017-06-20

No results posted yet for this study

Summary

Muscle invasive (MIBC) and/or metastatic bladder cancer is associated with poor prognosis and no target therapies for this pathology are currently validated. By 40 gene expression signature realized on frozen samples, we have previously identified an aggressive sub-class of MIBC, called basal. This sub-class (20% of MIBC) showed strong EGFR dependence in vitro and in vivo (Rebouissou et al. Science Translational Medicine 2014). This observation suggests a possible response to EGFR targeted therapy in patients of this subgroup. Our aim is to establish a standard diagnostic tool to differentiate the basal subtype of bladder cancer and evaluate the effect of anti-EGFR therapy, by analyzing previous clinical trial (GETUG19) and preclinical models, which compare the classical chemotherapy to anti-EGFR associated chemotherapy.

Conditions

Interventions

OTHER

biomarker study

Sponsors & Collaborators

  • Ministry of Health, France

    collaborator OTHER_GOV

  • National Cancer Institute, France

    collaborator OTHER_GOV

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • Paris 12 Val de Marne University

    collaborator OTHER

  • Institut Curie

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Yves ALLORY, MD, PhD · Assistance Publique - Hôpitaux de Paris

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02648100 on ClinicalTrials.gov